Baxter International, Inc.

Baxter International, Inc.

Baxter International, Inc.

Overview
Date Founded

1931

Headquarters

ONE BAXTER PARKWAY, DEERFIELD, IL, 60015

Type of Company

Public

Employees (Worldwide)

50K

Industries

Medical Products & Equipment
Pharmaceuticals
Wholesale: Medical Supplies & Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2011 sales of $13.9 billion and has approximately 48,500 employees.

Contact Data
Trying to get in touch with decision makers at Baxter International, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Corporate Vice President & President

Executive Vice President & Chief Financial Officer

Senior Vice President & General Counsel

Senior Vice President, Chief Science & Technology Officer

Senior Vice President & Chief Information Officer

Chief Accounting Officer, Senior Vice President & Controller

General Manager, US Hospital Products

General Manager, Acute Therapies

General Manager, Chronic Renal

Board of Directors

President & Chief Executive Officer at Baxter International, Inc.

Br Manager at Baxter HealthCare Corporation

Chairman & Chief Executive Officer at O-I Ltd.

Chief Executive Officer at Wellmark Blue Cross Blue Shield

Paths to Baxter International, Inc.
Potential Connections via
Relationship Science
You
Baxter International, Inc.
Owners & Shareholders
Details Hidden

Wellington Management's investment services rely on their extensive independent research and include portfolio management styles and approaches in equities, fixed income securities, currencies and commodities, as well as asset allocation across these categories. The firm has a number of different disciplines when approaching research and these include asset allocation analysts, currency analysts, data scientists, factor analysts, fixed income credit analysts, fixed income market analysts, global industry analysts and research associates, macroanalysts, quantitative analysts and technical analysts. Wellington Management's portfolio management teams often include dedicated analysts who evaluate securities and other instruments for suitability based on the team's investment approach. The firm supplements their internal research with external research from sources such as broker/dealers and third-party research firms. These sources typically provide data, research and analysis and may serve as a gauge of market consensus.

Details Hidden

MSIML is an active manager which performs bottom-up fundamental research to analyze the industries and companies in which they invest. Research and investment ideas are generated by the London-based Research Cooperative which fosters both intra- and inter-team communications through regular meetings. Their investment strategies span the risk/return spectrum across geographies, investment styles and asset classes, including equity, fixed income, alternatives and private markets. MSIML's portfolio management teams have ultimate responsibility for constructing portfolios. The team structure maximizes each team member's contribution to the investment process, while ensuring that a senior investor is always accountable for final decisions. Research is conducted by dedicated teams specializing in a particular niche of the fixed income market. The research teams use in-depth fundamental analysis, complemented by quantitative tools, to generate bottom-up investment ideas and are responsible for security selection.

Details Hidden

Third Point employs an event-driven, value-oriented strategy that spans a broad range of industries, geographies and asset classes. The funds' investment program may utilize certain investment techniques and strategies, including leverage and short sales, and may purchase certain types of securities, such as derivatives, futures, swaps, options, mortgage-backed and other asset-backed securities or other financial instruments, which can, in certain circumstances, substantially increase the adverse impact to which the funds may be subject. The firm identifies opportunities using a combination of top-down asset allocation decisions and a bottom-up, value-oriented approach to single security analysis. Third Point prefers event-driven situations, in which they believe that a catalyst, either intrinsic or extrinsic, will unlock value or alter conditions through which the greater market values a particular investment.

Recent Transactions
Details Hidden

Baxter International, Inc. purchases Sanofi /Seprafilm Brand from Sanofi

Details Hidden

Baxter International, Inc. purchases Cheetah Medical, Inc. from MVM Partners LLP, Ascension Ventures LLC, Fletcher Spaght Venture Partners LLC, Eastward Capital Partners LLC, Robert Bosch Venture Capital GmbH, HighCape Partners Management LLC

Details Hidden

Baxter International, Inc. purchases True Process, Inc.

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onBaxter International, Inc. issued USD Common Stock

Legal Advisor

Advised onBaxter International, Inc. purchases Prism Pharmaceuticals, Inc. from Paul Capital Partners LP, Essex Woodlands Management, Inc.

Underwriter

Advised onBaxter International, Inc. issued USD Common Stock

Legal Advisor

Advised onBaxter International, Inc. purchases Prism Pharmaceuticals, Inc. from Paul Capital Partners LP, Essex Woodlands Management, Inc.

Legal Advisor

Advised onBaxter International, Inc. purchases SuppreMol GmbH from Bayern Kapital GmbH, MIG Verwaltungs AG, ATS Beteiligungsverwaltung GmbH, Zcube SRL, BioMedPartners AG

Legal Advisor

Advised onCHF Solutions, Inc. purchases Baxter International, Inc. /Aquadex Business from Baxter International, Inc.

Advisors & Consultants
Legal Advisor

Partner at Foley Hoag LLP

Advisor

Managing Director at RBC Capital Markets LLC

Legal Advisor

Chair, Securities Litigation & Enforcement Practice Group at Willkie Farr & Gallagher LLP

Clients

DaVita is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of September 30, 2012, DaVita operated or provided administrative services at 1,912 outpatient dialysis centers in 43 states in the United States, serving approximately 150,000 patients, and at 24 centers in five countries outside of the United States that serve approximately 1,000 patients.

Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded by Benjamin J. Shaw in 2014 and is headquartered in Portland, ME.

MacroGenics is a leader in the discovery and development of innovative medicinces that utilize our next generation antibody-based technologies. Our team of 150+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases. Our products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe. Our innovative product candidates leverage our fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three proprietary technology platforms: Our Dual-Affinity Re-Targeting (DART™) platform enables us to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule; Our Fc Optimization platform enhances the natural immune system's ability to mediate killing of cancer cells; and Our Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy.

Key Stats and Financials As of 2019
Market Capitalization
$44.4B
Total Enterprise Value
$46.1B
Earnings Per Share
$1.93
Five Year Compounded Annual Growth Rate Of Revenue
-7.38%
Three Year Compounded Annual Growth Rate Of Revenue
3.79%
Total Equity
$7.91B
EBITDA
$2.7B
Total Debt
$5.96B
TEVNet Income
46.01x
Debt TEV
0.13x
Enterprise Value EBITDAOperating
16.85x
Enterprise Value Sales
4.05x
EBITDAMargin
23.74%
Revenue
$11.4B
Net Profit
$1B
Non-Profit Donations & Grants
$20K - $50K
2019
$25K - $50K
2019
Investments
Details Hidden

Sigma International General Medical Apparatus LLC manufactures drug-error prevention intravenous infusion pumps. It offers Sigma Spectrum for drug error prevention, Single-Doser for small volume medications and accessories. The company was founded in 1982 by Roger L. Hungerford and is headquartered in Medina, NY.

Details Hidden

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Details Hidden

Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the developing next-generation cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor (\"GM-CSF\") neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.

Suppliers
SciClone Pharmaceuticals Inc. Biotechnology | Foster City, California

SciClone Pharmaceuticals is a US-based, China-focused specialty pharmaceutical company with a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone’s ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Besides ZADAXIN, SciClone markets about 14 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California.

Ligand Pharmaceuticals, Inc. Medical Support Services | La Jolla, CA

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Vectura Group Plc Pharmaceuticals | Chippenham, United Kingdom

Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.

Awards & Honors
Rank #286
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #286
2016
Fortune Magazine - Fortune 500 Companies
Sponsored by Fortune Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Baxter International, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Baxter International, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Baxter International, Inc..